Weltruza is a drug owned by Teva Neuroscience Inc. It is protected by 4 US drug patents filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 10, 2044. Details of Weltruza's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12220418 | Olanzapine Compositions And Methods Of Use |
Jan, 2044
(17 years from now) | Active |
| US11813359 | Sustained Release Olanzapine Formulations |
Oct, 2038
(11 years from now) | Active |
| US10646443 | Sustained Release Olanzapine Formulations |
Mar, 2038
(11 years from now) | Active |
| US9023897 | Biodegradable drug delivery compositions |
Apr, 2033
(6 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Weltruza is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Weltruza's family patents as well as insights into
ongoing legal events
on those patents.
Weltruza's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Weltruza:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Generic Launch
Generic Release Date:
Weltruza's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 10, 2044 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Weltruza Generic API suppliers:
Olanzapine is the generic name for the brand Weltruza. 35 different companies have already filed for the generic of Weltruza, with Ajanta Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Weltruza's generic
Alternative Brands for Weltruza
There are several other brand drugs in the same treatment category and using the same active ingredient (Olanzapine) as Weltruza. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Alkermes Inc |
| |||||||||
| Indivior |
| |||||||||
| Intra-cellular |
| |||||||||
| Janssen Pharms |
| |||||||||
| Otsuka |
| |||||||||
| Otsuka Pharm Co Ltd |
| |||||||||
| Sunovion Pharms Inc |
| |||||||||
| Teva |
| |||||||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Olanzapine. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Alkermes Inc |
| |||
| Cheplapharm |
| |||
| Lilly |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Olanzapine, Weltruza's active ingredient. Check the complete list of approved generic manufacturers for Weltruza
About Weltruza
Weltruza is a drug owned by Teva Neuroscience Inc. Weltruza uses Olanzapine as an active ingredient. Weltruza was launched by Teva in 2026.
Approval Date:
Weltruza was approved by FDA for market use on 08 October, 2026.
Active Ingredient:
Weltruza uses Olanzapine as the active ingredient. Check out other Drugs and Companies using Olanzapine ingredient
Dosage:
Weltruza is available in powder form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 531MG/VIAL | POWDER | Prescription | SUBCUTANEOUS |
| 318MG/VIAL | POWDER | Prescription | SUBCUTANEOUS |
| 425MG/VIAL | POWDER | Prescription | SUBCUTANEOUS |
